-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A new study led by Yale Cancer Center researchers finds that enfortumab vedotin is effective in patients with muscle-invasive bladder cancer (MIBC) who are not eligible for cisplatin chemotherapy
"The findings are significant and encouraging because of the low survival rates for muscle-invasive bladder cancer
In this trial, investigators recruited patients diagnosed with MIBC who were not candidates for cisplatin-based chemotherapy but who were candidates for surgery
Petrylak added: "We look forward to conducting a Phase 3 study to further evaluate the efficacy of enfortumab vedotin